Expand ARWR Menu
ARWR MENU

ARWR Latest Press Releases

-- December 8, 2025 --

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies Business Wire 7:30 AM

-- December 2, 2025 --

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia Business Wire 7:30 AM

-- December 1, 2025 --

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences Business Wire 4:00 PM

-- November 25, 2025 --

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results Business Wire 4:00 PM

-- November 24, 2025 --

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics Business Wire 7:30 AM

-- November 18, 2025 --

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) Business Wire 11:52 AM

-- November 6, 2025 --

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results Business Wire 4:30 PM

-- November 4, 2025 --

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences Business Wire 7:30 AM

-- October 28, 2025 --

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- October 21, 2025 --

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis Business Wire 7:30 AM

-- October 7, 2025 --

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia Business Wire 7:30 AM

-- September 11, 2025 --

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals Business Wire 7:30 AM

-- September 10, 2025 --

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies Business Wire 7:30 AM

-- September 2, 2025 --

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement Business Wire 7:30 AM

-- August 27, 2025 --

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences Business Wire 7:30 AM

-- August 13, 2025 --

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics Business Wire 4:10 PM

-- August 7, 2025 --

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results Business Wire 4:01 PM

-- August 1, 2025 --

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi Business Wire 6:30 AM

-- July 28, 2025 --

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics Business Wire 7:30 AM

-- July 24, 2025 --

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- July 23, 2025 --

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics Business Wire 8:00 AM

-- July 21, 2025 --

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results Business Wire 4:01 PM
Market Data Delayed 15 Minutes